Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. (Q55041777)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. (English)

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

phase III clinical trial

0 references

head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck carcinoma

1 reference

based on heuristic

inferred from title

Everett E Vokes

14

object named as

Everett E Vokes

1 reference

Europe PubMed Central

16 June 2018

1

object named as

Fadlo R Khuri

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

17

object named as

Waun Ki Hong

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

3

object named as

Scott M Lippman

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

author name string

J Jack Lee

2

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Edward S Kim

4

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Jay S Cooper

5

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Steven E Benner

6

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Rodger Winn

7

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Thomas F Pajak

8

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Brendell Williams

9

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

George Shenouda

10

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Ian Hodson

11

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Karen Fu

12

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Dong M Shin

13

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Lei Feng

15

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Helmuth Goepfert

16

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

language of work or name

0 references

publication date

1 April 2006

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Journal of the National Cancer Institute

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

98

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

7

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

441-450

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

13-cis-retinoic acid in the treatment of oral leukoplakia

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Adjuvant treatment of stage I lung cancer with high-dose vitamin A.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Retinoids in lung cancer: friend, foe, or fellow traveler?

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ091

21 January 2018

Identifiers

10.1093/JNCI/DJJ091

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

1 reference

Europe PubMed Central

16 June 2018

http://europepmc.org/abstract/MED/16595780

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55041777&oldid=2077260203"